Cargando…
Immediate need for next-generation and mutation-proof vaccine to protect against current emerging Omicron sublineages and future SARS-CoV-2 variants: An urgent call for researchers and vaccine companies – Correspondence
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
IJS Publishing Group Ltd. Published by Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467924/ https://www.ncbi.nlm.nih.gov/pubmed/36108909 http://dx.doi.org/10.1016/j.ijsu.2022.106903 |
| _version_ | 1784788299441766400 |
|---|---|
| author | Chakraborty, Chiranjib Bhattacharya, Manojit Sharma, Ashish Ranjan Mohapatra, Ranjan K. Chakraborty, Sandip Pal, Soumen Dhama, Kuldeep |
| author_facet | Chakraborty, Chiranjib Bhattacharya, Manojit Sharma, Ashish Ranjan Mohapatra, Ranjan K. Chakraborty, Sandip Pal, Soumen Dhama, Kuldeep |
| author_sort | Chakraborty, Chiranjib |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9467924 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | IJS Publishing Group Ltd. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94679242022-09-13 Immediate need for next-generation and mutation-proof vaccine to protect against current emerging Omicron sublineages and future SARS-CoV-2 variants: An urgent call for researchers and vaccine companies – Correspondence Chakraborty, Chiranjib Bhattacharya, Manojit Sharma, Ashish Ranjan Mohapatra, Ranjan K. Chakraborty, Sandip Pal, Soumen Dhama, Kuldeep Int J Surg Correspondence IJS Publishing Group Ltd. Published by Elsevier Ltd. 2022-10 2022-09-13 /pmc/articles/PMC9467924/ /pubmed/36108909 http://dx.doi.org/10.1016/j.ijsu.2022.106903 Text en © 2022 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Correspondence Chakraborty, Chiranjib Bhattacharya, Manojit Sharma, Ashish Ranjan Mohapatra, Ranjan K. Chakraborty, Sandip Pal, Soumen Dhama, Kuldeep Immediate need for next-generation and mutation-proof vaccine to protect against current emerging Omicron sublineages and future SARS-CoV-2 variants: An urgent call for researchers and vaccine companies – Correspondence |
| title | Immediate need for next-generation and mutation-proof vaccine to protect against current emerging Omicron sublineages and future SARS-CoV-2 variants: An urgent call for researchers and vaccine companies – Correspondence |
| title_full | Immediate need for next-generation and mutation-proof vaccine to protect against current emerging Omicron sublineages and future SARS-CoV-2 variants: An urgent call for researchers and vaccine companies – Correspondence |
| title_fullStr | Immediate need for next-generation and mutation-proof vaccine to protect against current emerging Omicron sublineages and future SARS-CoV-2 variants: An urgent call for researchers and vaccine companies – Correspondence |
| title_full_unstemmed | Immediate need for next-generation and mutation-proof vaccine to protect against current emerging Omicron sublineages and future SARS-CoV-2 variants: An urgent call for researchers and vaccine companies – Correspondence |
| title_short | Immediate need for next-generation and mutation-proof vaccine to protect against current emerging Omicron sublineages and future SARS-CoV-2 variants: An urgent call for researchers and vaccine companies – Correspondence |
| title_sort | immediate need for next-generation and mutation-proof vaccine to protect against current emerging omicron sublineages and future sars-cov-2 variants: an urgent call for researchers and vaccine companies – correspondence |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467924/ https://www.ncbi.nlm.nih.gov/pubmed/36108909 http://dx.doi.org/10.1016/j.ijsu.2022.106903 |
| work_keys_str_mv | AT chakrabortychiranjib immediateneedfornextgenerationandmutationproofvaccinetoprotectagainstcurrentemergingomicronsublineagesandfuturesarscov2variantsanurgentcallforresearchersandvaccinecompaniescorrespondence AT bhattacharyamanojit immediateneedfornextgenerationandmutationproofvaccinetoprotectagainstcurrentemergingomicronsublineagesandfuturesarscov2variantsanurgentcallforresearchersandvaccinecompaniescorrespondence AT sharmaashishranjan immediateneedfornextgenerationandmutationproofvaccinetoprotectagainstcurrentemergingomicronsublineagesandfuturesarscov2variantsanurgentcallforresearchersandvaccinecompaniescorrespondence AT mohapatraranjank immediateneedfornextgenerationandmutationproofvaccinetoprotectagainstcurrentemergingomicronsublineagesandfuturesarscov2variantsanurgentcallforresearchersandvaccinecompaniescorrespondence AT chakrabortysandip immediateneedfornextgenerationandmutationproofvaccinetoprotectagainstcurrentemergingomicronsublineagesandfuturesarscov2variantsanurgentcallforresearchersandvaccinecompaniescorrespondence AT palsoumen immediateneedfornextgenerationandmutationproofvaccinetoprotectagainstcurrentemergingomicronsublineagesandfuturesarscov2variantsanurgentcallforresearchersandvaccinecompaniescorrespondence AT dhamakuldeep immediateneedfornextgenerationandmutationproofvaccinetoprotectagainstcurrentemergingomicronsublineagesandfuturesarscov2variantsanurgentcallforresearchersandvaccinecompaniescorrespondence |